ArticleRevista medica del Instituto Mexicano del Seguro Social2026
[Acute pancreatitis as first manifestation of systemic lupus erythematosus].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease with a broad clinical spectrum; gastrointestinal involvement can occur at any stage. SLE-associated pancreatitis is infrequent and exceptional as an initial manifestation, but it is associated with high morbidity and mortality. The objective was to describe a case of severe acute pancreatitis as the initial presentation of SLE and highlight its diagnostic and prognostic relevance. Case report: A 22-year-old female with no significant medical history and a history of inflammatory arthralgia was admitted for intense abdominal pain and intractable vomiting. Acute pancreatitis was documented, progressing to severe necrotizing pancreatitis (Balthazar E), complicated by respiratory failure and admission to the intensive care unit. Given the absence of common risk factors and the presence of hemolytic anemia, a thorough immunological workup was performed, confirming autoimmunity with positive antinuclear and anti-dsDNA antibodies, diagnosing de novo SLE. Patient received high doses of corticosteroid treatment and immunosuppressive therapy, with a favorable clinical outcome. Conclusions: Lupus pancreatitis is a marker of high systemic activity and severity, often underestimated by indices such as SLEDAI. Its timely recognition is fundamental to optimize the prognosis, requiring a multidisciplinary approach with early intensive support and immunosuppressive treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.